Abstract
Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. It is now well established that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being implicated in various types of AGE-related disorders such as diabetic vascular complications, neurodegenerative diseases and cancers. Further, there is accumulating evidence that AGEs and their receptor RAGE interaction elicits oxidative stress generation and subsequently alters gene expression in various types of cells. In addition, digested food-derived AGEs are found to play an important role in the pathogenesis of the AGE-related disorders as well. Indeed, restriction of diet-derived AGEs not only blocks the progression of atherosclerosis and renal injury, but also improves insulin resistance in animal models. AGE-poor diets reduce serum levels of inflammatory biomarkers in patients with diabetes or chronic renal failure. These observations suggest that the restriction of food-derived AGEs or the inhibition of absorption of dietary AGEs may be a novel target for therapeutic intervention in the AGE-related disorders. In this paper, we review the pathological role of food-derived AGEs in various types of disorders and discuss the potential utility of oral adsorbent that inhibits the absorption of AGEs in these devastating diseases.
Keywords: Dietary AGEs, oral adsorbent, atherosclerosis, chronic kidney disease, diabetic vascular complications
Current Pharmaceutical Design
Title: Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders
Volume: 13 Issue: 27
Author(s): Sho-ichi Yamagishi, Seiji Ueda and Seiya Okuda
Affiliation:
Keywords: Dietary AGEs, oral adsorbent, atherosclerosis, chronic kidney disease, diabetic vascular complications
Abstract: Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. It is now well established that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being implicated in various types of AGE-related disorders such as diabetic vascular complications, neurodegenerative diseases and cancers. Further, there is accumulating evidence that AGEs and their receptor RAGE interaction elicits oxidative stress generation and subsequently alters gene expression in various types of cells. In addition, digested food-derived AGEs are found to play an important role in the pathogenesis of the AGE-related disorders as well. Indeed, restriction of diet-derived AGEs not only blocks the progression of atherosclerosis and renal injury, but also improves insulin resistance in animal models. AGE-poor diets reduce serum levels of inflammatory biomarkers in patients with diabetes or chronic renal failure. These observations suggest that the restriction of food-derived AGEs or the inhibition of absorption of dietary AGEs may be a novel target for therapeutic intervention in the AGE-related disorders. In this paper, we review the pathological role of food-derived AGEs in various types of disorders and discuss the potential utility of oral adsorbent that inhibits the absorption of AGEs in these devastating diseases.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Ueda Seiji and Okuda Seiya, Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders, Current Pharmaceutical Design 2007; 13 (27) . https://dx.doi.org/10.2174/138161207781757051
DOI https://dx.doi.org/10.2174/138161207781757051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Perivascular Adipose Tissue as an Endocrine Organ: The Role of Statins
Current Pharmaceutical Design Systemic Approach to Parenteral Nutrition in the ICU
Current Drug Safety Schizophrenia-associated Risk and Protective Variants of c-Fos Encoding Gene
Recent Advances in DNA & Gene Sequences (Discontinued) Estrogen Activates Classical and Alternative Mechanisms to Orchestrate Neuroprotection
Current Neurovascular Research Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Nano Technological Approaches for Anti-tumour Therapy: Opportunities and Challenges
Nanoscience & Nanotechnology-Asia Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Prostanoid Receptors as Possible Targets for Anti-Allergic Drugs: Recent Advances in Prostanoids on Allergy and Immunology
Current Drug Targets The Escalating Challenge of Vancomycin Resistance in Staphylococcus aureus
Current Drug Targets - Infectious Disorders 1α ,25(OH)2-Vitamin D3 and 17β-Estradiol: Two Steroid Partners Acting in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Vascular Endothelial Growth Factor Gene as the Genetic Marker of Atherothrombotic Disorders and in the Gene Therapy of Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?
Current Medicinal Chemistry Medicinal Herbs Effective for Gray Hair in Traditional Persian Medicine
Current Traditional Medicine The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Clopidogrel in Secondary Ischemic Stroke Prevention
Recent Patents on Cardiovascular Drug Discovery Cytochrome P450 4A Fatty Acid Omega Hydroxylases
Current Drug Metabolism Cytokine and Immune System Abnormalities in Fibromyalgia and Other Central Sensitivity Syndromes
Current Rheumatology Reviews Network Effect of Wt-mutant p53 Interactions and Implications on p53 Gene Therapy
Current Pharmaceutical Design Modulation of Regulatory T Cells in Health and Disease: Role of Toll-Like Receptors
Inflammation & Allergy - Drug Targets (Discontinued)